Results 151 to 160 of about 71,079 (262)

Risk of Major Congenital Malformations Associated With the First-Trimester Exposure to Antipsychotics: A Large Claims Database Study. [PDF]

Pharmacol Res Perspect
Obara R, Sakai T, Ishikawa T, Morishita K, Adomi M, Hara A, Kikuchi S, Kobayashi N, Iwama N, Shinoda G, Noda A, Orui M, Ishikuro M, Tomita H, Mano N, Kuriyama S, Obara T.   +16 more
europepmc   +1 more source

A scoping review of service user experiences of potential harm in early intervention in psychosis services in the UK

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives Early intervention in psychosis (EIP) services provide care for individuals experiencing first‐episode psychosis and are considered both clinically and cost‐effective. While many have positive experiences of EIP, there have also been reports of perceived harm.
Georgie Hudson, India Francis‐Crossley, Craig S. Mackie, Rachel Hiller, James B. Kirkbride, Claire Powell   +5 more
wiley   +1 more source

Correction: Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes. [PDF]

CNS Drugs
Wang E, Liu Y, Wang Y, Han X, Zhou Y, Zhang L, Tang Y.   +6 more
europepmc   +1 more source

Contributions of worry and social anxiety to paranoia in clinical and non‐clinical samples: Cross‐sectional and longitudinal results

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives Theoretical models implicate social anxiety and worry as potential drivers of paranoia; however, it is unknown which aspect of anxiety relates more strongly to paranoia, whether these relationships differ in clinical versus non‐clinical populations and how these variables relate to one another over time.
Brandee Feola, Hao Wu, Stephan Heckers, Jennifer U. Blackford, Neil D. Woodward, Jinyuan Liu, Julia M. Sheffield   +6 more
wiley   +1 more source

Antipsychotics-Associated Allergic Reaction: A Case Report and Review of Literature. [PDF]

Clin Med Insights Case Rep
Sadeghi F, Momenzadeh M, Panahishokouh M.   +2 more
europepmc   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, EarlyView.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source